Tedd leads scientific development of the Life Edit Therapeutics gene editing platform. He has more than 20 years of biotech experience focused on gene expression and pharmaceutical discovery, and was previously Chief Scientific Officer at LifeEDIT Inc., when the company was a subsidiary of AgBiome.

Prior to this, Tedd was a Co-Founder, Vice President, and Director of Research at GrassRoots Biotechnology, which was subsequently acquired by Monsanto. In addition, he directed research for pharmaceutical discovery at Cropsolution, Inc.

Tedd received his Ph.D. in Biochemistry from the University of California, Davis and his B.S. in Biochemistry and Math from the University of Wisconsin, Madison.

Clare leads corporate development and strategy at Life Edit Therapeutics. She has more than 20 years of pharmaceutical industry experience focused on drug discovery and business development, and previously ran business development at LifeEDIT Inc., when the company was a subsidiary of AgBiome.

Prior to joining Life Edit, Clare held business development and leadership roles at Evotec and Aptuit, including running Aptuit’s U.S.—based Strategic Alliance Management team. In addition, she directed business development at SCYNEXIS, a start-up focused on infectious disease discovery and development for both human and animal health.

Clare received her Ph.D. in Organic Chemistry from the University of Liverpool and holds an MBA from The Fuqua School of Business at Duke University. She also received her B.S. from the University of Liverpool.

Joel leads the Computational Biology and Bioinformatics group at Life Edit Therapeutics. He has more than 20 years of experience in design, operations, and analysis of large scale genetic and genomic experiments.

Prior to joining Life Edit, Joel led the Lineberger Bioinformatics Shared Resource at University of North Carolina and was an Associate Professor in the Department of Genetics, where he remains an Adjunct Associate Professor. Joel’s Ph.D. efforts under Chuck Perou and continuing work with Nanostring resulted in Prosigna, the first FDA-approved IVDMIA with indications in breast cancer. He also co-developed RNA-sequencing programs at Expression Analysis (now Q2 Solutions) for The Cancer Genome Atlas. He subsequently co-founded Select Immunogenomics, which was acquired by GeneCentric in 2019. His broad scientific collaborations encompass >250 peer-reviewed manuscripts with an h-index > 100.

Joel received his Ph.D. in Bioinformatics and Computational Biology from the University of North Carolina and holds an M.S. in Biomedical Informatics from Vanderbilt University. He also received his B.S. in Biology and Computer Science from the University of Tennessee.

As Senior Director, Lead Development at Life Edit Therapeutics, Michael specializes in using protein engineering and bioconjugation to create novel therapeutics and utilizes his interdisciplinary background to evaluate and optimize them.

He previously held several positions at early-stage life sciences companies, including Applied Molecular Transport and Amunix, and focused on advancing delivery technologies for protein-based therapeutics.

Michael received his Ph.D. in Chemistry from the University of California, Berkeley, where he developed new methods to study cell signaling at membrane-membrane interfaces. Michael also holds a B.A. in Biochemistry and Molecular Biology from Boston University.

Phil is responsible for testing and validation of the gene editing systems in human cells across platform development and therapeutic areas at Life Edit Therapeutics.

Prior to joining Life Edit, he worked at Janelia Research Campus, Howard Hughes Medical Center’s flagship research institution, where he engineered genetically encoded sensors for neurotransmitters and small molecules.

Phil received his Ph.D. in Biology from Johns Hopkins University, where he studied the developmental interactions between the sympathetic nervous system and pancreatic islets. He also holds a B.A. in Biochemistry and Molecular Biology from Boston College.

Ron leads technology development in gene editing at Life Edit Therapeutics. He has more than 25 years of experience in the biotech industry, focusing on developing and applying innovative protein platforms for enzyme and protein therapeutic applications.

Prior to joining Life Edit, Ron led engineering efforts as a Director of Platform Development at a CRISPR startup, Arbor Biotechnologies. Prior to this, Ron spent 20 years at New England Biolabs (NEB) leading a research group engineering enzymes and developing protein platforms that enable high throughput cell-free protein synthesis and assay.

Ron received his Ph.D. in Pharmacognosy (Medicinal Chemistry) from the University of Michigan at Ann Arbor and B.S. in Biochemistry and Plant Physiology from Peking University in Beijing, China.